Chemotherapy + Herceptin Improves Response Rate in Patients with Advanced Disease.

2000 DEC 26 - (NewsRx.com & NewsRx.net) -- The addition of weekly Taxol (paclitaxel) plus Paraplatin (carboplatin) to Herceptin (trastuzamab) improves patient response and disease control in metastatic, or advanced, breast cancer that overexpresses the HER-2 neu oncogene.

This is according to a study at the 23rd annual San Antonio Breast Cancer Symposium, held in San Antonio, Texas, during December 2000.

In this trial, which was conducted by The Sarah Cannon Cancer Center, Nashville, Tennessee, among 46 patients evaluable for response, 25% responded to first-line Herceptin and continued to receive the HER-2 neu antibody alone. Among patients who had weekly …